EDE, The Netherlands--(BUSINESS WIRE)--Medisse B.V., announced the closure of a Series B equity financing round for the clinical trial of its lead product FlexiSurge® Adhesion Barrier. New investor IIG joins the existing investors, BioGeneration Ventures and Omnes Capital in the round. In addition Medisse will receive an innovation credit from the Dutch Ministry of Economic Affairs. Medisse is active in resorbable implants for soft tissue applications, based on a patented flexible polymer platform.
